Cardiovascular Research

Reprogramming cells for transplantation.

Authors: Jonathan Leor|||Alexander Battler|||Robert A Kloner|||Sharon Etzion

Affiliations: + Expand

Abstract

The field of tissue engineering, involving the reprogramming of stem cells or rejuvenation of specific differentiated cells, is emerging as a promising strategy to repair the damaged myocardium. The eventual goal is to be able to take a patient's own cells, expand them ex vivo, genetically engineer them to enhance specific properties, and then reintroduce them into the patient's heart to create a replacement tissue. Our review paper describes data that supports the potential of this strategy. This clinically relevant, combined strategy of genetic and tissue engineering could be of importance in treating elderly patients with massive myocardial damage, patients whose normal myogenic or angiogenic cells have been depleted or are inadequate in their growth potential, to prevent LV deterioration and heart failure.

---

Reference List

Nature. 1996 Mar 7;380(6569):64-6|||Circulation. 2002 Sep 24;106(12 Suppl 1):I270-6|||Lancet. 2001 Jan 27;357(9252):279-80|||Curr Opin Cardiol. 2002 Jul;17(4):346-52|||J Mol Cell Cardiol. 2002 Jul;34(7):717-24|||J Mol Cell Cardiol. 1999 Nov;31(11):2037-47|||J Clin Invest. 1998 May 15;101(10):2119-28|||Circulation. 1996 Sep 15;94(6):1394-401|||Circulation. 2002 Jan 29;105(4):522-9|||Ann Thorac Surg. 1995 Jul;60(1):12-8|||Nat Biotechnol. 2002 Jul;20(7):689-96|||Circulation. 2002 Sep 24;106(12 Suppl 1):I125-30|||Drug Discov Today. 2001 Dec 1;6(23):1231-1237|||Nat Med. 2000 Dec;6(12):1395-8|||Circulation. 1999 Jan 19;99(2):201-5|||Circ Res. 1993 Dec;73(6):1202-7|||Ann Thorac Surg. 2000 Jan;69(1):14-23; discussion 23-4|||Gene Ther. 1998 Jan;5(1):19-30|||J Mol Cell Cardiol. 1994 Oct;26(10):1393-401|||Nat Biotechnol. 2000 Jan;18(1):39-42|||J Thorac Cardiovasc Surg. 2001 Oct;122(4):759-66|||Circulation. 2001 Sep 18;104(12 Suppl 1):I308-I3|||Nat Biotechnol. 1999 Dec;17(12):1171-4|||Genes Dev. 1991 Aug;5(8):1377-86|||Circulation. 2000 Nov 7;102(19 Suppl 3):III210-5|||Curr Control Trials Cardiovasc Med. 2001;2(5):208-210|||Heart. 2001 Nov;86(5):574-8|||Cardiovasc Res. 1997 Sep;35(3):431-41|||J Mol Cell Cardiol. 1997 Mar;29(3):949-59|||J Mol Cell Cardiol. 2001 May;33(5):907-21|||J Clin Invest. 1996 Dec 1;98(11):2512-23|||J Am Coll Cardiol. 2000 Apr;35(5):1323-30|||Circulation. 2000 May 9;101(18):E182-7|||J Mol Cell Cardiol. 2001 Jul;33(7):1321-30|||Nature. 2002 Sep 12;419(6903):132-3|||Circulation. 2001 Sep 18;104(12 Suppl 1):I218-22|||Nat Rev Cancer. 2002 Aug;2(8):627-33|||J Thorac Cardiovasc Surg. 1995 May;109(5):918-23; discussion 923-4|||J Cell Biol. 2000 May 1;149(3):731-40|||Nat Med. 1998 Aug;4(8):929-33|||Nat Biotechnol. 2000 Jan;18(1):22-3|||Circulation. 2002 Aug 27;106(9):1133-9|||J Clin Invest. 1996 Nov 15;98(10):2209-17|||Circulation. 2000 Aug 22;102(8):898-901|||Circulation. 1999 Aug 3;100(5):468-74|||Eur J Cardiothorac Surg. 2002 May;21(5):853-7|||Nature. 2002 Jan 10;415(6868):234-9|||J Mol Cell Cardiol. 1996 Oct;28(10):2057-67|||Surg Annu. 1993;25 Pt 1:157-73|||N Engl J Med. 2002 Jun 13;346(24):1845-53|||J Clin Invest. 1998 Jan 15;101(2):337-43|||Heart. 2001 Nov;86(5):559-62|||Neurol Sci. 2000;21(5 Suppl):S943-51|||J Mol Cell Cardiol. 1996 Jan;28(1):133-40